Telmisartan
- Generic Name
- Telmisartan
- Brand Names
- Actelsar Hct, Micardis, Micardis-hct, Pritor, Twynsta, Tolura, Kinzalmono (previously Telmisartan Boehringer Ingelheim Pharma KG), Telmisartan Teva Pharma, Telmisartan Actavis
- Drug Type
- Small Molecule
- Chemical Formula
- C33H30N4O2
- CAS Number
- 144701-48-4
- Unique Ingredient Identifier
- U5SYW473RQ
- Background
Telmisartan is an angiotensin II receptor antagonist (ARB) used in the management of hypertension. Generally, angiotensin II receptor blockers (ARBs) such as telmisartan bind to the angiotensin II type 1 (AT1) receptors with high affinity, causing inhibition of the action of angiotensin II on vascular smooth muscle, ultimately leading to a reduction in arter...
- Indication
Used alone or in combination with other classes of antihypertensives for the treatment of hypertension. Also used in the treatment of diabetic nephropathy in hypertensive patients with type 2 diabetes mellitus, as well as the treatment of congestive heart failure (only in patients who cannot tolerate ACE inhibitors).
- Associated Conditions
- Cardiovascular Events, Diabetic Nephropathy, Heart Failure, Hypertension
- Associated Therapies
- -
Post-Marketing Surveillance of Micardis® (Telmisartan) in Patients With Hypertension
- First Posted Date
- 2014-09-17
- Last Posted Date
- 2014-09-17
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 6336
- Registration Number
- NCT02242838
Study Describing the Hypertensive Population Treated With Telmisartan and Conditions of Use by Medical Practitioners and Patients
- First Posted Date
- 2014-09-17
- Last Posted Date
- 2014-09-17
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 5018
- Registration Number
- NCT02242851
Evaluation of Efficacy and Tolerability of Micardis® / MicardisPlus® Under Usual Daily-practice Prescribing in Patients With Hypertension
- Conditions
- Interventions
- First Posted Date
- 2014-09-17
- Last Posted Date
- 2014-09-17
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 13248
- Registration Number
- NCT02242383
Evaluation of the Safety, Efficacy and Pharmacokinetics of MICARDIS® (Telmisartan) in Children and Adolescents With Hypertension
- First Posted Date
- 2014-09-17
- Last Posted Date
- 2017-12-28
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 77
- Registration Number
- NCT02242344
Study to Evaluate Efficacy of Micardis® (Telmisartan) and Valsartan in Patients With Mild-to-moderate Hypertension After Missing One Dose Using Ambulatory Blood Pressure Monitoring
- First Posted Date
- 2014-09-17
- Last Posted Date
- 2014-09-17
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 440
- Registration Number
- NCT02242318
Telmisartan Effectiveness on Left Ventricular Mass Reduction (TELMAR) as Assessed by MRI, in Patients With Mild to Moderate Hypertension
- Conditions
- Interventions
- First Posted Date
- 2014-09-17
- Last Posted Date
- 2014-09-17
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 24
- Registration Number
- NCT02242812
TELSYS - TELmisartan Effectiveness in Isolated SYStolic Hypertension Versus Systolic/Diastolic Hypertension Patients Aged 55 or Older
- Conditions
- Interventions
- First Posted Date
- 2014-09-17
- Last Posted Date
- 2014-09-17
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 3320
- Registration Number
- NCT02242877
Observation of Therapy With Micardis® (Telmisartan) in Patients With Essential Hypertension in Hospitals
- First Posted Date
- 2014-09-12
- Last Posted Date
- 2014-09-12
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 2318
- Registration Number
- NCT02238262
The Pharmacokinetic Drug-drug Interaction and Safety of Telmisartan/Amlodipine and Rosuvastatin in Healthy Male Volunteers
- Conditions
- Interventions
- First Posted Date
- 2014-09-08
- Last Posted Date
- 2015-02-18
- Lead Sponsor
- Yuhan Corporation
- Target Recruit Count
- 60
- Registration Number
- NCT02233218
- Locations
- 🇰🇷
Dong-A university hospital, Pusan, Korea, Republic of
Tolerability and Pharmacokinetics of Telmisartan in Combination With Lacidipine in Healthy Male Subjects
- First Posted Date
- 2014-08-18
- Last Posted Date
- 2014-08-18
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 27
- Registration Number
- NCT02218684
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.